Arrayjet secures £350,000 Beijing order
Arrayjet’s technology will assist further research into a range of medical conditions such as chromosome abnormalities and the blood disorder, Thalassemia.
This is a groundbreaking contract for Arrayjet as it continues its growing international reputation across the globe.
Detection kits designed for clinical diagnosis constitute an important part of CapitalBio Corporation’s products and services – the parent company operates four research institutes and five subsidiaries – and clinical diagnosis based on DNA detection is increasingly recognised and accepted by doctors and patients. As a result, the market for CapitalBio’s detection kits is expanding fast.
Iain McWilliam, chief executive of Arrayjet said: “CapitalBio is one of the most respected names in the global life sciences field and this contract is hugely significant for us, helping to further our aims in the Far East.
“Moreover, the past year has seen keen interest in our range of Arrayjet instrumentation products from North America, Australia and now China, so I am delighted that our international focus continues to attract high quality biomedical and life science service providers.
“his is a significant coup for a growing Scottish life science instrumentation company which now has dynamic international reach.”
Arrayjet has received financial support from Archangels, the Scottish-based business angel syndicate.
Archangels director, Mike Rutterford said: “This is yet another excellent contract achieved by Arrayjet and the ‘brand’ appears to becoming synonymous across the world with delivering instrumentation which has the precision and accuracy sought by many of the world’s top laboratories and science parks.
“Arrayjet is destined to be the partner of choice for so many of these research establishments.”